Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention (ASSEE-SHD)
Establishment of Active Surveillance and Safety and Efficacy Evaluation Indicators for Innovative Devices Used in Interventional Treatment of Structural Heart Disease
This study aims to establish an active surveillance system to evaluate the safety and effectiveness of innovative medical devices used in the interventional treatment of structural heart disease. The devices of interest include a biodegradable patent foramen ovale (PFO) closure device and a transcatheter mitral valve edge-to-edge repair system. Clinical information from patients receiving these devices during routine clinical care will be collected and analyzed. The findings will help evaluate the safety and effectiveness of these devices and support the development of appropriate clinical evaluation indicators and long-term monitoring strategies.
Aperçu de l'étude
Statut
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xinyi Xu
- Numéro de téléphone: +86 18930830756
- E-mail: 3342@scmc.com.cn
Sauvegarde des contacts de l'étude
- Nom: Kai Wang
- Numéro de téléphone: +86 15317921903
- E-mail: 30192@scmc.com.cn
Lieux d'étude
-
-
-
Beijing, Chine
- Pas encore de recrutement
- Beijing Anzhen Hospital, Capital Medical University
-
Contact:
- Yizhen Yang
- Numéro de téléphone: +86 13261985610
- E-mail: yangyizhen2005@126.com
-
Chercheur principal:
- Wenhui Wu
-
Beijing, Chine
- Pas encore de recrutement
- FUWAI Hospital, CAMS&PUMC
-
Contact:
- Jing Dong
- Numéro de téléphone: +86 15810174302
- E-mail: Djing0324@163.com
-
Chercheur principal:
- Guangzhi Zhao
-
Shanghai, Chine
- Pas encore de recrutement
- East Hospital, Tongji University
-
Contact:
- Ying Hao
- Numéro de téléphone: +86 18049898248
- E-mail: supergreathy@163.com
-
Chercheur principal:
- Linxiang Lu
-
-
Gansu
-
Lanzhou, Gansu, Chine
- Recrutement
- The First Hospital of Lanzhou University
-
Contact:
- Sixiong Hu
- Numéro de téléphone: +86 17693433056
- E-mail: hsx1120587348@126.com
-
Chercheur principal:
- Jizhe Xu
-
-
Guangdong
-
Guangzhou, Guangdong, Chine
- Pas encore de recrutement
- Guangdong Provincial People's Hospital
-
Contact:
- Xiaotong Wen
- Numéro de téléphone: +86 18123548072
- E-mail: 1127337995@qq.com
-
Chercheur principal:
- Caojin Zhang
-
-
Henan
-
Zhengzhou, Henan, Chine
- Recrutement
- Fuwai Central China Cardiovascular Hospital
-
Contact:
- Menghao Li
- Numéro de téléphone: +86 18790660032
- E-mail: edward564@163.com
-
Chercheur principal:
- Shubo Song
-
-
Hubei
-
Wuhan, Hubei, Chine
- Recrutement
- Zhongnan Hospital of Wuhan University
-
Contact:
- Lei Wang
- Numéro de téléphone: +86 18702797617
- E-mail: 119559295@qq.com
-
Chercheur principal:
- Gangcheng Zhang
-
-
Liaoning
-
Shenyang, Liaoning, Chine
- Pas encore de recrutement
- General Hospital of Northern Theater Command, Chinese People's Liberation Army
-
Chercheur principal:
- Qiguang Wang
-
Contact:
- Jiawang Xiao
- Numéro de téléphone: +86 17790991821
- E-mail: xjw492918837@126.com
-
-
Shandong
-
Jinan, Shandong, Chine
- Pas encore de recrutement
- Shandong Provincial Hospital
-
Contact:
- mingliang Dong
- Numéro de téléphone: +86 13573157896
- E-mail: dongmingliang2008@126.com
-
Chercheur principal:
- Anbiao Wang
-
-
Sichuan
-
Chengdu, Sichuan, Chine
- Pas encore de recrutement
- Sichuan Provincial People's Hospital
-
Contact:
- Xuechun Sun
- Numéro de téléphone: +86 18981838108
- E-mail: sunxchun@163.com
-
Chercheur principal:
- Yunshan Cao
-
-
Yunnan
-
Kunming, Yunnan, Chine
- Pas encore de recrutement
- Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences/Affiliated Cardiovascular Hospital of Kunming Medical University
-
Chercheur principal:
- Cheng Wang
-
Contact:
- Kairui Yang
- Numéro de téléphone: +86 13987313055
- E-mail: 416719379@qq.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
- Biodegradable PFO Closure Device Cohort: Patients with confirmed PFO-associated ischemic stroke who undergo implantation of a biodegradable PFO closure device.
- Transcatheter Mitral Valve Edge-to-Edge Repair (TEER) Cohort: Patients with functional or degenerative mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a TEER system.
La description
Inclusion Criteria:
- Patients undergoing implantation of a biodegradable PFO closure device.
- Patients undergoing transcatheter mitral valve edge-to-edge repair.
Exclusion Criteria:
The participant expresses a desire to withdraw from the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Biodegradable Patent Foramen Ovale Closure Device
Participants with patent foramen ovale (PFO) who receive a biodegradable PFO closure device as part of routine clinical care will be included in this cohort. Clinical data will be collected to evaluate the safety and effectiveness of the device during follow-up. |
|
Transcatheter Mitral Valve Edge-to-Edge Repair System Cohort
Participants with degenerative or functional mitral regurgitation who undergo transcatheter mitral valve edge-to-edge repair using a transcatheter mitral valve edge-to-edge repair system. Safety and effectiveness outcomes will be assessed during follow-up. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Major Adverse Events
Délai: At 1, 6, and 12 months after the procedure
|
Incidence of major adverse events related to the biodegradable PFO closure or transcatheter mitral valve edge-to-edge repair procedure during follow-up. |
At 1, 6, and 12 months after the procedure
|
|
Anatomical success of PFO closure within 12 months after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography
Délai: At 1, 6, and 12 months after the procedure
|
The proportion of participants achieving successful anatomical closure of the patent foramen ovale (PFO) during the 12-month follow-up period after biodegradable PFO occluder implantation, assessed by transthoracic echocardiography. |
At 1, 6, and 12 months after the procedure
|
|
Incidence of the composite clinical outcome of heart failure hospitalization, all-cause mortality, or cardiovascular mortality within 12 months after transcatheter edge-to-edge mitral valve repair
Délai: At 1, 6, and 12 months after the procedure
|
The proportion of participants experiencing at least one of the following events during the 12-month follow-up period after TEER: hospitalization for heart failure, all-cause death, or cardiovascular death. Events will be assessed through clinical follow-up and review of medical records. |
At 1, 6, and 12 months after the procedure
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Degree of device degradation
Délai: At 1, 6, and 12 months after the procedure
|
The degree of degradation of the biodegradable PFO closure device will be assessed by echocardiography during follow-up. |
At 1, 6, and 12 months after the procedure
|
|
Incidence of residual shunt after PFO closure
Délai: At 1, 6, and 12 months after the procedure.
|
The presence of residual shunt after implantation of the biodegradable PFO closure device will be assessed by echocardiography with contrast study, when applicable. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of re-intervention after PFO closure
Délai: At 1, 6, and 12 months after the procedure.
|
The percentage of participants requiring reapeat intervention or surgical treatment related to the PFO closure device during follow-up. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of recurrent stroke after PFO closure
Délai: At 1, 6, and 12 months after the procedure.
|
The occurrence of recurrent ischemic or hemorrhagic stroke during the follow-up period will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of device-related thrombosis after PFO closure
Délai: At 1, 6, and 12 months after the procedure.
|
The occurrence of thrombosis related to the biodegradable PFO closure device during follow-up will be assessed by echocardiography and clinical assessment. |
At 1, 6, and 12 months after the procedure.
|
|
Proportion of participants who underwent TEER and achieved immediate procedural success
Délai: Within 24 hours after the procedure.
|
Immediate procedural success is defined as successful completion of the transcatheter mitral valve edge-to-edge repair procedure with post-procedural mitral regurgitation (MR) grade ≤2+, as assessed by echocardiography. |
Within 24 hours after the procedure.
|
|
Incidence of subsequent open-heart surgery in the TEER group
Délai: At 1, 6, and 12 months after the procedure.
|
The number of participants undergoing subsequent open-heart surgery related to TEER during follow-up. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of ischemic or hemorrhagic stroke in the TEER group
Délai: At 1, 6, and 12 months after the procedure.
|
The occurrence of ischemic or hemorrhagic stroke during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
|
Incidence of bleeding events in the TEER group
Délai: At 1, 6, and 12 months after the procedure.
|
The occurrence of bleeding events during follow-up in the TEER group will be assessed by clinical evaluation and review of medical records. |
At 1, 6, and 12 months after the procedure.
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Lijun Fu, Shanghai Children's Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- SCMC2024ZD0527503
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant-level data relevant to the study objectives, including baseline characteristics, procedural data, safety and efficacy outcomes, and follow-up data, will be shared.
Délai de partage IPD
Start Date: 12 months after publication of the primary results End Date: No end date
Critères d'accès au partage IPD
De-identified individual participant-level data and supporting information will be available to qualified researchers upon reasonable request and subject to review and approval by the study investigators. Access will be provided for scientifically justified research purposes in accordance with applicable regulations and data protection requirements. Requests should be submitted to the study investigators, and approved data will be shared through a secure data transfer mechanism.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- RSE
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .